Valproate: Clinical Pharmacological Profile

Bipolar Psychopharmacotherapy: Caring for the Patient

Volumn , Issue , 2006, Pages 27-42

  Bowden, Charles L ^a   Singh, Vivek ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Bipolar depression; Dysphoric and euphoric mania; Mania with depressive features; Placebo monotherapy study; Serum level response relationships; Stress regulated kinases; Valproate in bipolar disorder

Indexed keywords

EID: 84889339786     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/0470017953.ch3     Document Type: Chapter

References (63)

1. Bowden CL. Efficacy of Divalproex vs. Lithium and Placebo in Mania. JAMA. 1994; 272: 1005-1006.
2. Bowden CL. Valproate. Bipolar Disord. 2003; 5: 189-202.
3. Bowden CL. Predictors of response to divalproex and lithium. J. Clin. Psychiatry. 1995; 56: 25-30.
4. Bowden CL. Relationship of acute mania symptomatology to maintenance treatment response. Curr. Psychiatry Rep. 2004; Dec. 6(6): 473-477.
5. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, Dilsaver SC, Davis JM, Rush AJ, Small JG, Garza-Trevino ES, Risch SC, Goodnick PJ, Morris DD. Efficacy of divalproex vs lithium and placebo in the treatment of mania. JAMA. 1994; 271: 918-924.
6. Bowden CL, Calabrese JR, McElroy SL, Gyulai L, Wassef A, Petty F, Pope HG, Jr., Chou JC-Y, Keck PE, Jr., Rhodes LJ, Swann AC, Hirschfeld RMA, Wozniak PJ. A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder. Arch. Gen. Psychiatry. 2000; 57: 481-489.
7. Bowden CL, Collins MA, McElroy SL, Calabrese JR, Swann AC, Weisler RH, Wozniak PJ. Relationship of Mania Symptomatology to maintenance treatment response with divalproex lithium or Placebo. Neuropsychopharmacology. 2005; June 8. (online pub: 3 May 2005 at http://www.acnp.org/citations/NPP050305040404/default.pdf).
8. Brunello N, Tascedda F. Cellular mechanisms and second messengers: relevance to the psychopharmacology of bipolar disorders. Int. J. Neuropsychopharmacol. 2003; 6: 181-189.
9. Burton BS. On the propyl derivatives and decomposition products of ethyl acetoacetate. Am. Chem. J. 1881; 3: 385-395.
10. Calabrese JR, Markovitz PJ, Kimmel SE, Wagner SC. Spectrum of efficacy of valproate in 78 rapid-cycling bipolar patients. J. Clin. Psychopharmacol. 1992; 12: 53S-56S.
11. Casey DE, Daniel DG, Wassef AA, Tracy KA, Wozniak P, Sommerville KW. Effect of divalproex combined wth olanzapine or risperidone in patients with an acute exacerbation of schizophrenia. Neuropsychopharmacology. 2003; 28: 182-192.
12. Chen G, Masana MI, Manji HK. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord. 2000; 2: 217-236.
13. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol. Bull. 2004; 32: 647-652.
14. Deltito J, Martin L, Riefkohl J, Austria B, Kissilenko A, Corless P, Morse C. Do patients with borderline personality disorder belong to the bipolar spectrum ? J. Affect. Disord. 2001; 67: 221-228.
15. DeSarno P, Li X, Jope RS. Regulation of Akt and glycogen synthas kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology. 2002; 43: 1158-1164.
16. Einat H, Yuan P, Gould TD, Li J, Du J, Zhang L, Manji HK, Chen G. The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 2003; 23: 7311-7316.
17. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: A double-blind placebo-controlled pilot study. J. Clin. Psychiatry. 2002; 63: 442-446.
18. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am. J. Psychiatry. 1992; 149: 108-111.
19. Ghaemi SN, Goodwin FK. Long-term naturalistic treatment of depressive symptoms in bipolar illness with divalproex, vs lithium in the setting of minimal antidepressant use. J. Affect. Disord. 2001; 65: 281-287.
20. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J, Rivicki D. Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA. 2003; 290: 1467-1473.
21. Gould TD, Manji HK. The Wnt signaling pathway in bipolar disorder. Neuroscientist. 2002; 8: 497-511.
22. Gould TD, Chen G, Manji HK. In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology. 2004; 29: 32-38.
23. Gray NA, Zhou R, Du J, Moore GJ, Manji HK. The use of mood stabilizers as plasticity enhancers in the treatment of neuropsychiatric disorders. J. Clin. Psychiatry. 2003; 64(S): 3-17.
24. Grunze H, Erfurth A, Amann B, Giupponi G, Kammerer C, Walden J. Intravenous valproate loading in acutely manic and depressed bipolar I patients. J. Clin. Psychopharmacol. 1999; 19: 303-309.
25. Harwood AJ, Agam G. Search for a common mechanism of mood stabilizers. Biochem. Pharmacol. 2003; 66: 179-189.
26. Hollander E, Lopez AA, Bienstock CA, Grossman R, Siever LJ, Merkatz L, Stein DJ (2001), A preliminary double-blind, placebo controlled trial of divalproex sodium in borderline personality disorder. J. Clin. Psychiatry. 62: 199-203.
27. Jacobsen FM. Low dose valproate: A new treatment for cyclothymia, mild rapid cycling disorders, and premenstrual syndrome. J. Clin. Psychiatry. 1993; 54: 229-234.
28. Kahn D, Stevenson E, Douglas CJ. Effect of sodium valproate in three patients with organic brain syndromes. Am. J. Psychiatry. 1988; 145: 1010-1011.
29. Keck PE, Meinhold JM, Prihoda TJ, Baker JD, Wozniak PJ, Bowden CL. Relation of serum valproate and lithium concentrations to efficacy and tolerability in maintenance therapy for bipolar disorder. Accepted for publication by "Psychiatry in Clinical Practice", 2005.
30. Kowatch RA, Suppes T, Carmody TJ, Bucci JP, Hume JH, Kromelis MR, Emslie GJ, Weinberg WA, Rush AJ. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J. Am. Acad. Child Adolesc. Psychiatry. 2002; 39: 713-720.
31. Lambert PA, Cavaz G, Borselli S, Carrel S. Action neuropsychotrope d'un nouvel anti-epileplique: Le Depamide. Ann. Med. Psychol. 1966; 1: 707-710.
32. Lambert PA, Venaud G. A comparative study of valpromide versus lithium in the prophylaxis of thymic disorders. J. Psychiatry, Published by Maxmed. 1992; 5(2): 57-65.
33. Lieb K, Treffurth Y, Hamke M, Akundi RS, von Kleinsorgen M, Fiebich BL. Valproic acid inhibits substance P-induced activation of proten in kinase C epsilon and expression of the substance P receptor. J. Neurochem. 2003; 86: 69-76.
34. Macritchie KA, Geddes JR, Scott J, Haslam DR, Goodwin GM. Valproic acid, valproate and divalproex in the maintenance treatment of bipolar disorder. Psychiatr. Serv. 2000; 51: 1179-1181.
35. McElroy SL, Keck PE, Stanton SP, Tugrul KC, Bennett JA, Strakowski SM. A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. J. Clin. Psychiatry. 1996; 57: 142-146.
36. Muller-Oerlinghausen B, Retzow A, Henn FA, Giedke H, Walden J. Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: A prospective, randomized, double-blind, placebo-controlled, multicenter study. J. Clin. Psychopharmacol. 2000; 20: 195-203.
37. Petty F, Davis LL, Nugent AL, Kramer GL, Teten A, Schmitt A, Stone RC. Valproate therapy for chronic, combat-induced postraumatic stress disorder. J. Clin. Psychopharmacol. 2002; 22: 100-101.
38. Pope HG, Jr., McElroy SL, Keck PE, Jr., Hudson JI. Valproate in the treatment of acute mania: A placebo-controlled study. Arch. Gen. Psychiatry. 1991; 48: 62-68.
39. Puzynski S, Klosiewicz L. Valproic acid amide in the treatment of affective and schizoaffective disorders. J. Affect. Disord. 1984; 6: 115-121.
40. Rasgon N. The relationship between polysystic ovary syndrome and antiepileptic drugs: A review of the evidence. J. Clin. Psychopharmacol. 2004; 24: 322-334.
41. Rasgon NL, Altshuler LL, Gudeman D, Burt VK, Tanavoli S, Hendrick V, Korenman S. Medication status and polycystic ovary syndrome in women with bipolar disorder: A preliminary report. J. Clin. Psychiatry. 2000; 61: 173-178.
42. Sachs G, Grossman F, Okamoto A, Ghaemi SN, Bowden CL. Risperidone plus mood stabilizer versus placebo plus mood stabilizer for acute mania of bipolar disorder: A double-blind comparison of efficacy and safety. Am. J. Psychiatry. 2002; 159: 1146-1154.
43. Seung Kim HF, Weeber EJ, Sweatt JD, Stoll AL, Marangell LB. Inhibitory effects of omega-3 fatty acids on protein kinase C activity in vitro. Mol. Psychiatry. 2001; 6: 246-248.
44. Siafaka-Kapadai A, Patiris M, Bowden C, Javors M. Incorporation of [3H]-Valproic Acid into Lipids in GT1-7 Neurons. Biochem. Pharmacol. 1998; 56: 207-212.
45. Stoll AL, Locke CA, Vuckovic A, Mayer PV. Lithium-associated cognitive and functional deficits reduced by a switch to divalproex sodium: A case series. J. Clin. Psychiatry. 1996; 57: 356-359.
46. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania. Am. J. Psychiatry. 1999; 156: 1264-1266.
47. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD. Pattern of response to divalproex, lithium, or placebo in four naturalistic subtypes of mania. Neuropsychopharmacology. 2002; 26: 530-536.
48. Swann AC, Secunda SK, Stokes PE, Croughan J, Davis JM, Koslow SH, Maas JW. Stress, depression, and mania: Relationship between perceived role of stressful events and clinical and biochemical characteristics. Acta Psychiatr. Scand. 1990; 81: 389-397.
49. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, Sachs GS, Kupfer JD, Ghaemi SN, Feldman PD, Risser RC, Evans AR, Calabrese JR. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br. J. Psychiatry. 2004; Apr. 184: 337-345.
50. Tohen M, Chengappa KNR, Suppes T, Zarate CA JR, Calabrese JR, Bowden CL, Sachs GS, Kupfer DJ, Baker RW, Risser RC, Keeter EL, Feldman PD, Tollefson GD, Breier A. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch. Gen. Psychiatry. 2002; 59: 62-69.
51. Tohen M, Castillo-Ruiz J, Pope HG Jr., Herbstein J. Concomitant use of valproate and carbamazepine in bipolar and schizoaffective disorders. J. Clin. Psychopharmacol. 1994; 14: 67-70.
52. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate monotherapy: Feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder. Psychopharmacology. 2000; 150: 15-23.
53. Watterson JM, Watson DG, Meyer EM, Lenox RH. A role for protein kinase C and its substrates in the action of valproic acid in the brain: Implications for neural plasticity. Brain Res. 2002; 934: 69-80.
54. Wilder BJ, Karas BJ, Penry JK, Asconape J. Gastrointestinal tolerance of divalproex sodium. Neurology. 1983; 33: 808-811.
55. Winsberg ME, DeGolia SG, Strong CM, Ketter TA. Divalproex therapy in medication-naïve and mood stabilizer-naïve bipolar II depression. J. Affect. Disord. 2001; 67: 207-212.
56. Yatham L. Safety and efficacy of risperidone as combination therapy for the manic phase of bipolar disorder: Preliminary findings of a randomized, double-blind study (Abstract). Presented at the 13th European College of Neuropsychopharmacology Congress, Munich, Germany, 2000.
57. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br. J. Psychiatry. 2003; 182: 141-147.
58. Yerevanian BI, Koek RJ, Mintz J. Lithium, anticonvulsants and suicidal behavior in bipolar disorder. J. Affect. Disord. 2003; 73: 223-228.
59. Young LT, Joffe RT, Robb JC, MacQueen GM, Marriott M, Patelis-Siotis I. Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression. Am. J. Psychiatry. 2000; 157: 124-126.
60. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK, Chen G. The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 2001; 276: 31674-83.
61. Zajecka J, Weisler RSKW. Divalproex Sodium Vs. Olanzapine for the Treatment of Mania in Bipolar Disorder. Presented at the 39th Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 2000.
62. Zajecka J, Weisler R, Sachs G, Swann AC, Wozniak P, Sommerville KW. A comparison of the efficacy, safety and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J. Clin. Psychiatry. 2002; 63: 1148-1155.
63. Zarate CA Jr., Tohen M, Narendran R, Tomassini EC, McDonald J, Sederer M, Madrid AR. The adverse effect profile and efficacy of divalproex sodium compared with valproic acid: A pharmacoepidemiology study. J. Clin. Psychiatry. 2000; 60: 232-236.